The exchange of materials between academic scientists is generally less problematic than the transfer between industry and science, mainly because the cultures and motivations of each institution involved in the exchange are similar. In the United States, most universities transfer material for academic research purposes under conditions that generally have no restrictions other than the obligation not to transfer the material to third parties without authorization or notice. These transfers are often made with UBMTA9 facilitated by the NIH, the NIH single letter agreement, or an equivalent benign agreement. The UBMTA contains a very narrow definition of the material to be transferred, and the agreement does not give a supplier any rights beyond the „original material, descendants and derivatives unchanged“. This narrow definition and lack of „reach“ towards new materials and research results are the hallmark of agreements between universities, which greatly facilitates these transfers. The most obvious and fundamental principle for academic researchers is to maintain the unlimited ability to publish their research results. Freedom of publication may be restricted by MTAs if the provider requires editorial rights to a publication or the right of permission and inference to refuse a publication. Publication restrictions can also manifest themselves indirectly in ATMs. For example, the material itself may be described as confidential, making meaningful publication impossible. Of particular concern are the serious consequences that a publication restriction can have for students whose future depends so much on publication. This is clearly a principle that a university cannot compromise, and the principle is so widespread that one would think it would not even be subject to discussion. Sometimes, however, this is the case.

An MTA is required whenever material is transferred between two or more parties. However, there are a few exceptions. The Office of Research and Sponsored Programs (ORSP) will review the circumstances and make a decision. Many institutions also have an MTA policy and may need their own documentation. Manual deliveries and pickups also require an agreement. Use of model agreements A long-recognized strategy to reduce costs and negotiation time is the use of standard or model agreements. In 1995, the NIH published the first and only generally accepted model agreements for the transfer of materials, the NIH Simple Letter Agreement for the Transfer of Materials (SLA) and the Uniform Biological Material Transfer Agreement (UBMTA), as well as guidelines for the transfer of research tools. The NIH urged fellows to ensure that the unique research resources resulting from NIH-funded research are made available to the scientific research community, either without formal agreement or under conditions or agreements that are no more restrictive than ESL for most materials, a requirement renewed by NRC.

Basically, an MTA is a deposit, that is, a transfer of tangible assets without a transfer of ownership. Under such an agreement, the supplier retains ownership of the transferred property. The transferred assets are held by the receiving party in accordance with the terms set out in a legally binding contract. The contract therefore governs the transfer of biological materials between two or more parties. In addition to the material property rights held by the supplier, the materials may be the subject of a patent or patent application. In this case, the MTA may need to consider the transfer of intellectual property rights as well as the transfer of equipment. The transfer of intellectual property rights would take the form of a license, i.B to manufacture, use, sell, etc., i.e. a license is an authorization to do something that would otherwise violate the intellectual property rights of the supplier. This chapter discusses documents to be used for research purposes, usually in the absence of a planned research collaboration between the provider and the recipient.

This cooperation could be ensured by a separate cooperation agreement that would accompany the ATM. The MTA defines the rights of the supplier and the consignee with regard to materials and derivatives of materials. *Some transfers may be subject to export control regulations. Please note the interim policy of 20.06.06. Some repositories require records and others require MTAs, and some require both. If you register to use a deposit or order specific material and the deposit requires an institutional signature, the documents must be submitted to the research department. With increasing regularity, the exchange of research material takes place within the framework of Material Transfer Agreements (MTAs). MTAs are legal agreements (sureties) that govern the transfer of tangible assets between the parties. For example, the University of California, Davis managed more than 470 MTAs in 2005, and that number had increased every year since 2001. At the same time, the complexity of MPAs increases significantly, with limitations and obligations that can extend far beyond the material itself, to data or inventions made using the material and/or derived materials.

As a result, each MTA has begun to assume the complexity of a licensing agreement, and it takes a high level of skill and time to ensure that the MTA can be executed without compromising key principles and not conflicting with other agreements. Therefore, an MTA can be a hybrid instrument that covers both the transfer of tangible assets (by deposit and contract) and intangible intellectual property (through patent rights licenses). To complicate matters further, the terms of an MTA can determine how future intellectual property rights arising from the use of the transmitted documents are assigned. An ATM should allow the recipient of the documents to publish or present the results of the recipient`s search using the documents without the consent of the provider. An MTA may require the recipient to send the supplier a copy of a proposed manuscript, abstract, poster session or presentation prior to such publication or presentation so that the supplier can review, comment or request deletion of the supplier`s confidential information. A review period of 30 to 45 days is sufficient for most providers and acceptable for most academic recipients. The ATM may require that publication or submission be delayed for an additional period to allow for the filing of patent applications. An additional 30 to 45 days is sufficient for most providers. .